FDA Approves Biosimilars Yesafili and Opuviz, Opening New Avenues for Affordable Eye Treatments
The FDA has recently approved two new biosimilars, Yesafili (aflibercept-jbvf) by Biocon Biologics and Opuviz (aflibercept-yszy) by Samsung…
Oak Hill Bio and Chiesi Resume Phase 2b Clinical Study for OHB-607 to Treat Bronchopulmonary Dysplasia
Oak Hill Bio and Chiesi Group have announced the enrollment of the first patient in a resumed Phase…